AxioMed Spine pulls in $5M to fuel pivotal lumbar disc trial

AxioMed Spine brought in $5 million in a wrap-up of its Series D financing. It plans to use the cash to finish clinical studies of its spinal orthopedics devices in the U.S. and boost marketing efforts in Europe.

The Garfield, OH company said it raised the money from previous and new investors. It also comes on top of the previously announced $15 million Series D financing.

Launched in 2001, AxioMed is developing next-generation disc implants to treat degenerative spinal diseases. Armed with the new cash infusion, the company expects to finish its U.S. pivotal study for the Freedom lumbar disc. Additionally, AxioMed will pursue a similar U.S. approval path for its cervical disc, which just gained a CE mark in the European Union.

Longer term, AxioMed faces a number of large competitors in the spinal implant space, including Smith & Nephew ($SNN), Medtronic ($MDT), Zimmer ($ZMH) and others. The company touts its products as standing out, however, because they help preserve spinal function, going beyond standard treatments such as fusion and first-generation discs. Smaller device companies, such as AxioMed, often end up being acquisition targets, however, once they reach certain clinical milestones.

- read the release

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.